Annals of Surgical Oncology, Vol 1, Issue 2 132-140, Copyright © 1994 by Society of Surgical Oncology

ARTICLES

Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings

J. P. Crowe Jr, L. P. Adler, R. R. Shenk and J. Sunshine
Department of Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio.

BACKGROUND: Positron emission tomography (PET) is a means of imaging tissue based upon its metabolic activity. Initial studies in the field of oncology suggest that PET may be useful for diagnosis, staging, and treatment of various tumors. METHODS: Twenty-eight patients with 37 breast lesions were studied with PET using [fluorine-18] 2-deoxy-2-fluoro-D-glucose (FDG) to assess which clinicopathological characteristics relate to FDG accumulation by the primary tumor. RESULTS: PET-FDG was found to successfully discriminate malignant from benign breast lesions (p = 0.02) and identify axillary lymph node metastases. FDG uptake by the primary tumor was found to be independent of age, menopausal status, race, tumor size, laterality, histologic differentiation, ploidy, DNA index, estrogen or progesterone receptor value, pathologic stage, and serum glucose. Higher tumor nuclear grade and S-phase were associated with more FDG accumulation by the primary tumor compared with normal breast tissue. PET-FDG correctly identified five malignant lesions that were indeterminant for cancer both on clinical breast examination and mammography and identified one occult cancer that was neither palpable nor apparent mammographically. PET-FDG correctly identified clinical occult axillary metastatic cancer in five patients. CONCLUSIONS: This study shows that PET-FDG imaging can distinguish malignant from benign breast lesions among a diverse group of patients and suggests that PET-FDG may not only allow for preoperative staging of patients but also provide information about prognosis. This study provides impetus for continued research into PET-FDG imaging of breast lesions, which could have a major impact on the treatment of breast cancer.

This article has been cited by other articles:

				H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213. [Abstract] [Full Text] [PDF]

				A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				U. Guller, E. Nitzsche, H. Moch, and M. Zuber Is Positron Emission Tomography an Accurate Non-invasive Alternative to Sentinel Lymph Node Biopsy in Breast Cancer Patients? J Natl Cancer Inst, July 16, 2003; 95(14): 1040 - 1043. [Full Text] [PDF]

				M N Maisey Overview of clinical PET Br. J. Radiol., November 1, 2002; 75(90009): S1 - 5. [Full Text] [PDF]

				C.-S. Liu, Y.-Y. Shen, C.-C. Lin, R.-F. Yen, and C.-H. Kao Clinical Impact of [18F]FDG-PET in Patients with Suspected Recurrent Breast Cancer Based on Asymptomatically Elevated Tumor Marker Serum Levels: a Preliminary Report Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 244 - 247. [Abstract] [Full Text] [PDF]

				S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]

				K. Murthy, M. Aznar, C. J. Thompson, A. Loutfi, R. Lisbona, and J. H. Gagnon Results of Preliminary Clinical Trials of the Positron Emission Mammography System PEM-I: A Dedicated Breast Imaging System Producing Glucose Metabolic Images Using FDG J. Nucl. Med., November 1, 2000; 41(11): 1851 - 1858. [Abstract] [Full Text] [PDF]

				G Cserni Axillary staging of breast cancer and the sentinel node J. Clin. Pathol., October 1, 2000; 53(10): 733 - 741. [Abstract] [Full Text] [PDF]

				P. B. Hathaway, D. A. Mankoff, K. R. Maravilla, M. M. Austin-Seymour, G. K. Ellis, J. R. Gralow, A. A. Cortese, C. E. Hayes, and R. E. Moe Value of Combined FDG PET and MR Imaging in the Evaluation of Suspected Recurrent Local-Regional Breast Cancer: Preliminary Experience Radiology, March 1, 1999; 210(3): 807 - 814. [Abstract] [Full Text]

				P. G. Rose, L. P. Adler, M. Rodriguez, P. F. Faulhaber, F. W. Abdul-Karim, and F. Miraldi Positron Emission Tomography for Evaluating Para-aortic Nodal Metastasis in Locally Advanced Cervical Cancer Before Surgical Staging: A Surgicopathologic Study J. Clin. Oncol., January 1, 1999; 17(1): 41 - 41. [Abstract] [Full Text] [PDF]